Skip to main content
Passa alla visualizzazione normale.

CHIARA CATALANO

Credibility assessment of patient-specific modeling in transcatheter aortic valve implantation—Part 2: Uncertainty quantification and sensitivity analysis

  • Authors: Scuoppo, R.; Catalano, C.; Turgut, T.; Gotzen, N.; Cannata, S.; Gentile, G.; Gandolfo, C.; Pasta, S.
  • Publication year: 2025
  • Type: Articolo in rivista
  • OA Link: http://hdl.handle.net/10447/691187

Abstract

Transcatheter aortic valve implantation (TAVI) benefits from patient-specific computational modeling, yet model credibility remains a challenge. The ASME V&V40 standard provides a framework for assessing uncertainty and sensitivity in in silico predictions, ensuring reliability in clinical decision-making. This study evaluates uncertainty quantification (UQ) and sensitivity analysis of a patient-specific TAVI model using the ASME V&V40 standard to enhance model credibility. Four patient-specific TAVI models with 23 and 26 mm SAPIEN 3 Ultra (S3) devices were developed using finite-element simulations for deployment and fluid-structure interaction analysis for hemodynamic analysis. Uncertain parameters included anatomical features, material properties, hemodynamic conditions, and procedural variables. A surrogate model was constructed with Gaussian-process regression, and probabilistic assessment was conducted via quasi-Monte Carlo analysis. Sensitivity analysis identified key parameters influencing model outputs. The surrogate model accurately predicted device diameter (mean relative error <1%), with balloon expansion volume and stent-frame material properties being the most influential. Hemodynamic predictions exhibited greater uncertainty, with effective orifice area and pressure gradient showing deviations beyond the 5% validation threshold. This study establishes a framework for UQ in patient-specific TAVI modeling, demonstrating reliable device deployment predictions. The findings support integrating in silico models into clinical decision-making, benefiting clinicians, manufacturers, and regulatory bodies. This study is complemented by a first part dedicated to the discrete validation of the patient-specific TAVI model against clinical data.